- Home
- PDD vs SNY Comparison
PDD vs SNY Comparison
Compare PDD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDD | SNY |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | Ireland | France |
| Employees | N/A | 74846 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.9B | 116.8B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | PDD | SNY |
|---|---|---|
| Price | $102.52 | $43.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $137.55 | $61.50 |
| AVG Volume (30 Days) | ★ 5.2M | 4.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.66% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.37 | $3.01 |
| Revenue Next Year | $14.82 | $5.80 |
| P/E Ratio | $10.63 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $87.12 | $43.51 |
| 52 Week High | $139.41 | $59.17 |
Technical Indicators
Market Signals| Indicator | PDD | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 31.33 |
| Support Level | $100.18 | N/A |
| Resistance Level | $104.25 | $48.97 |
| Average True Range (ATR) | 1.84 | 0.69 |
| MACD | 0.18 | -0.35 |
| Stochastic Oscillator | 39.84 | 2.19 |
Price Performance
Historical ComparisonAbout PDD PDD Holdings Inc.
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.